SAN FRANCISCO (GenomeWeb News) – Danaher will likely use at least part of its $8 billion available for acquisitions in order to expand its life science and diagnostics portfolio, company President and CEO Larry Culp said at the 32nd Annual JP Morgan Healthcare Conference here this morning.

During the firm’s analyst day meeting last month, Culp said that the firm had at its disposal about $8 billion available to pursue merger and acquisitions and today he reiterated that figure while adding that the firm “will continue to be an active acquirer” throughout 2014 and beyond.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.